众生药业(002317) - 2025 Q2 - 季度业绩预告

Current Period Performance Forecast This section outlines the company's semi-annual performance forecast for 2025, detailing the projected net profit and earnings per share Performance Forecast Period The company forecasts its semi-annual performance for 2025, covering financial results from January 1 to June 30, 2025 - The performance forecast period is from January 1, 2025, to June 30, 2025[3] Projected Performance Net profit attributable to shareholders for the first half of 2025 is projected to increase significantly by 94.49% to 140.25%, with non-recurring net profit expected to grow by 3.64% to 26.67% Key Performance Indicators Forecast for H1 2025 | Item | Current Period Forecast (CNY 10,000) | Prior Year Period (CNY 10,000) | Year-over-Year Change Range | | :-------------------------------- | :--------------------------------- | :----------------------------- | :-------------------------- | | Net Profit Attributable to Shareholders | 17,000 – 21,000 | 8,740.98 | Increase 94.49% – 140.25% | | Net Profit Excluding Non-Recurring Items | 18,000 – 22,000 | 17,368.16 | Increase 3.64% – 26.67% | | Basic Earnings Per Share (CNY/share) | 0.20 – 0.25 | 0.10 | - | Communication with Accounting Firm This section clarifies that the current performance forecast has not undergone pre-audit by a certified public accountant - This performance forecast has not been pre-audited by a certified public accountant[4] Explanation of Performance Changes The significant increase in net profit attributable to shareholders is primarily attributed to the reduced impact of non-recurring gains and losses compared to the prior year period - Net profit attributable to shareholders is projected to increase significantly by 94.49% to 140.25%, primarily due to the impact of non-recurring gains and losses in the prior year period[5] - Non-recurring gains and losses in the prior year period amounted to -86.2719 million yuan, mainly comprising fair value changes in tradable financial assets and provisions for pending litigation[5] - The impact of non-recurring gains and losses on net profit decreased in the current reporting period[5] Other Related Information This section provides disclaimers regarding the preliminary nature of the forecast and advises investors to exercise caution - This performance forecast represents preliminary estimates by the company's finance department and has not been audited by an accounting firm[7] - Specific financial data will be detailed in the company's 2025 semi-annual report[7] - The company advises investors to be aware of investment risks[7]